Lupin Ltd.
Last updated Jun 21, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
60%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Cardiovascular
- Antihypertensive
- Neurology
- Antiepileptic
Highest priority development: FDA AP — SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE (ORIG)
Regulatory precedent
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Lupin Ltd.; the same agency is already in play for this signal, so precedent weight is higher.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 60%
Active Signals
2
Investigate Priority
0
Opportunity Score
42
Buyer Quality
4 · Low Priority
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 21, 2026Score 21Lupin's ANDA078232 for Losartan Potassium Receives AP Status from FDA
Cardiovascular · Antihypertensive
- MonitorJun 19, 2026Score 21Lupin's Divalproex Sodium ANDA209286 Receives Abbreviated Approval
Neurology · Antiepileptic
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE (ORIG)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — LOSARTAN POTASSIUM (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — LOSARTAN POTASSIUM (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (ORIG)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Lupin Ltd. right now?
- Which regulatory precedents should Lupin Ltd. monitor in Cardiovascular and Antihypertensive?
- Which pipeline programs should Lupin Ltd. prioritize for competitive review?
- What signals require immediate investigation for Lupin Ltd.?
- Summarize the strategic implications of recent developments for Lupin Ltd..
- Where is the greatest uncertainty in Lupin Ltd.'s competitive positioning?